Egrifta (Tesamorelin): What It Is, Trial History and Regulatory Status

Evidence tier: Established (FDA-approved; multiple randomized controlled trials).

This page is for educational purposes only and is not medical advice; consult a licensed physician or your prescriber about any medication, including whether an approved product such as Egrifta is appropriate in a given clinical situation. Nothing below is a protocol, a recommendation, or an instruction to use anything.

What Egrifta Is

Egrifta is the trade name for tesamorelin, a synthetic analogue of human growth hormone-releasing factor (GRF, also called GHRH), developed and commercialised by Theratechnologies. Early drug evaluations described tesamorelin as a stabilised 44-amino-acid GRF analogue designed to resist rapid enzymatic degradation while retaining activity at the pituitary GHRH receptor (PMID 17086939). Reviews of the investigational programme characterised it as a secretagogue that stimulates the body's own pituitary somatotrophs rather than supplying exogenous growth hormone (PMID 19243281).

Mechanism as described in the literature

Reviews reported that tesamorelin binds pituitary GHRH receptors and increases endogenous, pulsatile growth hormone secretion, which in turn raises circulating insulin-like growth factor 1 (IGF-1) (PMID 19243281). Because growth hormone has lipolytic effects on visceral adipose tissue, investigators hypothesised that restoring GH pulsatility could address the accumulation of abdominal visceral fat seen in some people with HIV (PMID 22298602). A population pharmacokinetic and pharmacodynamic analysis in HIV-infected patients and healthy subjects modelled tesamorelin exposure together with IGF-1 as the pharmacodynamic marker, and researchers reported that the exposure–IGF-1 relationship could be described across both populations (PMID 25895899).

Approved indication

Egrifta received United States approval in 2010 for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. Contemporary reviews of the approved product described the labelled regimen as tesamorelin 2 mg administered subcutaneously once daily in this population (PMID 21668043), and independent reviews described the same 2 mg once-daily subcutaneous regimen as the dose carried through the registration programme (PMID 22050344). Those dose figures are reproduced here only as published label and trial facts, not as guidance for any individual.

The approval is narrow: it addresses excess visceral abdominal fat in the specific context of HIV-associated lipodystrophy. Reviewers emphasised that tesamorelin was not studied or approved as a general weight-loss agent, and that reductions were seen in visceral adipose tissue rather than in overall body weight (PMID 22298602).

Trial History as Published

The phase 3 randomized programme

The pivotal evidence base consists of randomized, double-blind, placebo-controlled trials in people with HIV and abdominal fat accumulation. One phase 3 trial randomized participants to tesamorelin 2 mg daily or placebo for 26 weeks and then continued into a safety extension phase, and researchers reported greater reduction in visceral adipose tissue with tesamorelin than with placebo (PMID 20101189). In that trial the study also examined lipid and safety endpoints alongside the imaging-based fat measurements over the 26-week randomized period and the subsequent extension (PMID 20101189).

Reviews that pooled the registration trials reported that tesamorelin 2 mg once daily reduced visceral adipose tissue relative to placebo over 26 weeks, with accompanying changes in triglycerides and other lipid measures, and without the loss of subcutaneous fat that would be undesirable in a lipodystrophy population (PMID 21668043). The same reviews reported that visceral fat tended to return toward baseline in participants who were switched from tesamorelin to placebo during extension periods, which reviewers interpreted as indicating that the effect depended on continued treatment (PMID 21668043). A separate review of the approved product reached broadly similar conclusions about the magnitude and durability of the visceral fat effect (PMID 22050344).

Liver-related and metabolic findings

Later analyses examined whether visceral fat reduction tracked with hepatic measures. One analysis in people with HIV reported that visceral fat reduction with tesamorelin was associated with improvement in liver enzymes (PMID 28832410). A mechanistic study in HIV-associated non-alcoholic fatty liver disease used targeted proteomic and transcriptomic profiling, and researchers reported response pathways that distinguished participants who responded to tesamorelin from those who did not (PMID 34006921). These were secondary and mechanistic analyses; they describe associations and biological pathways rather than approved indications.

Fat quality, not only fat quantity

An analysis published in AIDS reported that tesamorelin improved fat quality independent of changes in fat quantity, using imaging-derived measures of adipose tissue characteristics rather than volume alone (PMID 33756511). Researchers framed this as evidence that the compound's effects on adipose tissue were not captured solely by cross-sectional area measurements (PMID 33756511).

Newer trials in the modern antiretroviral era

Because antiretroviral regimens changed substantially after the original registration trials, investigators re-examined tesamorelin in people with HIV receiving integrase inhibitor–based therapy; that 2024 report in AIDS evaluated efficacy and safety endpoints in this contemporary population (PMID 38905488). A 2025 report in the Journal of Infectious Diseases examined effects of tesamorelin on neurocognitive impairment in persons with HIV and abdominal obesity, extending the endpoint set beyond body composition and metabolic measures (PMID 39813152). Readers interested in the exact endpoints, participant numbers and statistical results of these trials can consult the primary publications linked in the reference list.

Adverse Events in Trials and on the Label: What Studies Report

Reviews of the registration programme reported that the most frequently observed adverse events with tesamorelin were injection-site reactions, including erythema, pruritus and pain, together with musculoskeletal complaints such as arthralgia and myalgia, peripheral oedema, and sensory symptoms including paraesthesia and hypoaesthesia (PMID 21668043). Additional reviews reported nausea, rash and pruritus among treatment-emergent events, and noted that some participants discontinued because of injection-site or hypersensitivity-type reactions (PMID 22050344).

Because the mechanism raises growth hormone and IGF-1, laboratory changes received particular attention. Reviewers reported increases in IGF-1 during treatment and monitored glucose parameters closely, given the known potential of growth hormone excess to impair insulin sensitivity (PMID 22298602). In the phase 3 trial with a safety extension, the study tracked glucose-related and other safety laboratory measures alongside efficacy endpoints across the randomized and extension phases (PMID 20101189). The 2024 trial in participants on integrase inhibitors also reported safety outcomes in that contemporary treatment setting (PMID 38905488).

Label-level warnings stated factually

The United States prescribing information for tesamorelin products does not carry a boxed warning. The label includes contraindications and warnings that reflect the GH/IGF-1 mechanism, including considerations around active malignancy and neoplasm risk, disruption of the hypothalamic–pituitary axis, pregnancy, glucose intolerance and diabetes, fluid retention, hypersensitivity reactions, and monitoring of IGF-1. Published reviews discussed these same mechanism-linked concerns — neoplasia surveillance, glucose homeostasis and fluid retention — as the principal issues raised during development and regulatory review (PMID 21668043). Only a prescriber with access to a person's full history can weigh these label sections against an individual's circumstances, and the current approved labelling is the authoritative source.

Regulatory Status

Tesamorelin under the Egrifta name is an FDA-approved prescription medicine, not an investigational or unapproved substance. Its approval in 2010 for HIV-associated lipodystrophy made it the first product authorised in the United States specifically for the reduction of excess abdominal fat in that population, a point noted in reviews published shortly after approval (PMID 21668043). Approval status, labelling and product listings change over time; the authoritative current sources are FDA's Drugs@FDA database, the FDA drug shortage database and the manufacturer's approved prescribing information.

Supply and compounding, in general terms

Tesamorelin products have at times been affected by manufacturing and supply interruptions, and FDA's drug shortage database is the appropriate place to verify whether a specific tesamorelin presentation is currently listed as in shortage. Under United States compounding law, section 503A and 503B facilities are generally restricted from compounding drugs that are "essentially copies" of commercially available approved products, with limited statutory exceptions such as drugs appearing on FDA's shortage list. Whether any particular compounded preparation is lawful depends on current regulatory listings, state rules and professional judgement. This page describes published literature and general regulatory framing and is not legal advice.

How Egrifta Differs From Sibling Products With the Same Active Ingredient

Several branded presentations share tesamorelin as the active ingredient. They differ in formulation and presentation rather than in the molecule itself, and the labelled daily amount of tesamorelin described in reviews of the approved product was 2 mg subcutaneously once daily (PMID 21668043).

Because the active moiety is identical across these presentations, the trial evidence summarised above derives from studies of tesamorelin generally rather than from separate efficacy programmes for each presentation. Differences among presentations concern formulation, storage and the number of vials per daily amount — matters handled by the label and by a dispensing pharmacist, not by educational content.

What the Evidence Does and Does Not Establish

• Established: randomized, placebo-controlled trials in people with HIV and abdominal fat accumulation reported greater visceral adipose tissue reduction with tesamorelin than with placebo (PMID 20101189), and reviews of the registration programme reached the same conclusion (PMID 22050344).
• Mechanistically characterised: the compound acts as a GRF/GHRH analogue that raises endogenous growth hormone and IGF-1 (PMID 19243281), with exposure–IGF-1 relationships described in a population PK/PD analysis (PMID 25895899).
• Exploratory: associations with liver enzyme improvement (PMID 28832410), adipose tissue quality measures (PMID 33756511), hepatic response pathways (PMID 34006921) and neurocognitive endpoints (PMID 39813152) come from secondary, mechanistic or newer trials and do not define the approved indication.
• Not established: use outside the approved HIV-associated lipodystrophy indication, including general fat loss, anti-ageing or athletic contexts, is not supported by the registration evidence summarised in these reviews (PMID 22298602).

Questions a Reader Might Bring to a Prescriber

Decisions about prescription medication belong to a reader and their licensed clinician. Topics that appear repeatedly in the published literature, and that a prescriber is positioned to address, include how the approved indication applies to a given diagnosis, how glucose and IGF-1 are monitored given the mechanism-linked concerns reported in reviews (PMID 22298602), how injection-site and musculoskeletal adverse events reported in trials are managed (PMID 21668043), and what the reviews' observation that visceral fat returned toward baseline after switching to placebo implies for long-term planning (PMID 21668043).

PeptideU is not affiliated with or endorsed by Theratechnologies. Egrifta is a trademark of its owner. This page is for educational purposes only and is not medical advice; consult a licensed physician or your prescriber about any medication.

References

• Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor (Current Opinion in Investigational Drugs, 2006)
• Tesamorelin, a human growth hormone releasing factor analogue (Expert Opinion on Investigational Drugs, 2009)
• Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension (JAIDS, 2010)
• Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy (Drugs, 2011)
• Spotlight on tesamorelin in HIV-associated lipodystrophy (BioDrugs, 2011)
• Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy (The Annals of Pharmacotherapy, 2012)
• Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects (Journal of Pharmacokinetics and Pharmacodynamics, 2015)
• Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV (AIDS, 2017)
• Tesamorelin improves fat quality independent of changes in fat quantity (AIDS, 2021)
• Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach (Scientific Reports, 2021)
• Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors (AIDS, 2024)
• Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity (The Journal of Infectious Diseases, 2025)